Abiopharma

🔍 Galligan Andrew H (Executive)

Company: Arcellx, Inc. (ACLX)

Report Date: 2026-04-28

Detailed Transactions and Holdings:

• Sold 5,000 shares of Common Stock (Direct)
  Date: 2026-04-28 | Code: U | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
• Sold 16,829 shares of Stock Option (right to buy) at $69.87 per share (Derivative)
  Date: 2026-04-28 | Code: D | Expires: 2035-03-18 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F2
• Sold 1,784 shares of Stock Option (right to buy) at $63.68 per share (Derivative)
  Date: 2026-04-28 | Code: D | Expires: 2035-05-29 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F2

Footnotes:

• F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the "Merger Agreement"), by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share ("Closing Amount"), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a "CVR"), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent.
• F2: Pursuant to the Merger Agreement, each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than the Closing Amount, was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.